A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

This is an early-phase clinical trial testing a new targeted drug called CGT4859 in patients with a type of bile duct cancer (cholangiocarcinoma) or other advanced cancers that have a specific genetic change in the FGFR2 or FGFR3 genes. The goal is to find out if this drug is safe and whether it can shrink tumors in these patients. **You may be eligible if...** - You have advanced, metastatic, or inoperable bile duct cancer (intrahepatic cholangiocarcinoma) or another solid tumor - Your tumor has been confirmed to have an FGFR2 or FGFR3 genetic alteration - You have already received standard treatment, or standard treatment is not appropriate for you - Your cancer is measurable on scans - You have a good general performance status (able to carry out daily activities) - You are 18 years of age or older **You may NOT be eligible if...** - Your cancer has not been tested for FGFR2/3 alterations or does not have these changes - You have significant unresolved side effects from prior treatments - You have certain heart, eye, or other organ conditions that could be worsened by this drug Talk to your doctor to see if this trial is right for you.